Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
WaveForm Technologies developed a proprietary continuous glucose monitoring system ("Cascade CGM") that received CE Mark approval in Europe in 2019. The Cascade device featured needle-free insertion and reusable components to reduce pain, trauma, and biological waste compared to competitors. In January 2024, Trinity Biotech acquired all biosensor and CGM assets from WaveForm for $12.5 million plus shares and contingent consideration. The original Cascade device is no longer sold; Trinity Biotech plans to develop a next-generation sensor based on this technology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on WaveForm Technologies.